LABU News and Press, Direxion Daily S&P Biotech Bull 3X Shares From 06/28/22

Vertex Pharma develops, manufactures, and commercializes small molecule drugs for patients with serious diseases. The company has obtained approval for several products that treat forms of cystic fibrosis ("CF"). The firm’s drug pipeline includes treatments for sickle cell dise...

On Friday, BioMarin Pharmaceutical received a positive CHMP opinion in Europe for ValRox for Hemophilia type A treatment. According to the last report, the core portfolio looks solid. Vozxogo remains the main driver of revenue growth this year. If approved in Europe, the start...

Results from the phase 3 RESPONSE study, which is using Seladelpar for the treatment of patients with primary biliary Cholangitis, are expected in 2023. PBC patients treated with Seladelpar over a 2-year period saw a decrease in GLOBE PBC Score and improved transplant-free survival. ...

Repare Therapeutics is working in synthetic lethality, where big pharma has shown interest. They have some early data. While things look good, I will wait for more conclusive data before I jump in. For further details see: Repare Therapeutics: Interesting Gene Editing Co...

Gainers: Direxion Daily S&P Biotech Bull 3x Shares ETF (LABU) +70%. AXS 2X Innovation ETF (TARK) +50%. Direxion Daily Dow Jones Internet Bull 3X Shares (WEBL) +42%. Direxion Daily Select Large Caps & FANGs (FNGG) +40%. ProShares UltraShort Bloomberg Natural Gas (KOLD) +35%. Losers: Di...

UPRO is a leveraged ETF that offers investors daily investment results that correspond to three times (3x) the daily performance of the S&P 500 Index. The ETF is down more than -54% year to date. We believe we just saw the "fear" leg of this structural bear market unfold ...

BioCryst Pharmaceuticals shares have been clobbered due to both the bear market and the uncertainty relating to its lead developing drug (BCX9930). I believe that the FDA would remove the partial clinical hold on BCX9930 by either year-end or next year. The lead drug (Orladeyo) is...

As inflation rises and recession looms in, people tend to invest more in gold, which in turn is expected to benefit the gold miners’ equity shares and ETFs. Energy and commodity funds (including the leveraged bull funds) have generated growth during 2022, while gold funds have ...

Allogene's leadership position in allogeneic CAR-T can be rewarding for early investors. However, being a pioneer has its pitfalls. The company has a decent amount of cash. For further details see: Allogene Therapeutics: Multibagger Potential, But Terribly Risky

Since my last coverage in the previous quarter, LABU has been on a free fall for the past 12 weeks and also recorded a huge loss over the past 6. 3X funds like LABU have the highest expense ratio and  extreme levels of volatility. As the biotechnology sector is going through ...